On May 5, 2025, analyst Yi Chen from HC Wainwright & Co. reiterated a "Neutral" rating for CareDx (CDNA, Financial). Notably, the rating remains unchanged from the prior assessment, maintaining the same outlook for the stock's performance.
Additionally, HC Wainwright & Co. has maintained their price target for CareDx (CDNA, Financial) at $25.00 USD. This price target remains consistent with the prior evaluation, indicating no change in the projected market value for the stock.
The affirmation of the neutral rating alongside the stable price target suggests a steady outlook for CareDx (CDNA, Financial), reflecting a consistent evaluation from HC Wainwright & Co.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for CareDx Inc (CDNA, Financial) is $28.63 with a high estimate of $40.00 and a low estimate of $19.00. The average target implies an upside of 90.83% from the current price of $15.00. More detailed estimate data can be found on the CareDx Inc (CDNA) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, CareDx Inc's (CDNA, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CareDx Inc (CDNA, Financial) in one year is $18.44, suggesting a upside of 22.93% from the current price of $15. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CareDx Inc (CDNA) Summary page.
